Healthcare Cost of Over-Diagnosis of Low-Grade Dysplasia in Barrett’s Esophagus

Conclusions The healthcare cost of over-diagnosis of BE-LGD is significant. To reduce the overall healthcare cost impact of over-diagnosis of BE-LGD, strict adherence to the recommendations of the American Gastroenterological Association, American College of Gastroenterology, and American Society for Gastrointestinal Endoscopy that pathology review of all BE biopsy specimens be performed by a gastrointestinal pathologist is warranted.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research